NDA 021436 · Otsuka
Abilify
Aripiprazole · Oral · Atypical Antipsychotic
NovelOrphanLast checked: Nov 21, 2026Latest source record: Jan 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Nov 15, 2002
Approved uses
13
Original approval plus efficacy supplements
Registered trials
401
123 Phase 3, 18 recruiting
FAERS reports
117,169
79,602 serious, 6,592 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS WITH ANTIDEPRESSANT DRUGS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ABILIFY is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1) ] . Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24 years; there was a reduction in risk with antidepressant use in patients aged 65 years and older [see Warnings and Precautions (5.3) ] . In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for...
What it is approved for
From the label in effect Jan 29, 2025.
ABILIFY (aripiprazole) Tablets are indicated for the treatment of: Schizophrenia Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder Adjunctive Treatment of Major Depressive Disorder Irritability Associated with Autistic Disorder Treatment of Tourette's Disorder ABILIFY is an atypical antipsychotic. ABILIFY is indicated for: Schizophrenia ( 14.1 ) Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder ( 14.2 ) Adjunctive Treatment of Major Depressive Disorder ( 14.3 ) Irritability Associated with Autistic Disorder ( 14.4 ) Treatment of Tourette's Disorder ( 14.5 )
Mechanism: The mechanism of action of aripiprazole in schizophrenia or bipolar mania, is unclear. However, the efficacy of aripiprazole in the listed indications could be mediated through a combination of partial agonist activity at D 2 and 5-HT 1A receptors and antagonist activity at 5-HT 2A receptors.
Therapeutic areas: Psychiatry
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 12, 2014 Supplement 38 · Efficacy OrphanReviewLetterLabel
- Jun 9, 2014 Supplement 36 · Efficacy Pediatric Statistical ReviewPediatric Medical ReviewLabel
- Feb 16, 2011 Supplement 29 · Efficacy LetterPediatric Medical ReviewPediatric Statistical Review
- Nov 19, 2009 Supplement 27 · Efficacy ReviewLetterLabel
- May 6, 2008 Supplement 20 · Efficacy ReviewSummary ReviewLetter
- May 6, 2008 Supplement 19 · Efficacy ReviewLetterSummary Review
- Feb 27, 2008 Supplement 21 · Efficacy · priority review Pediatric Written RequestLetterLabel
- Nov 16, 2007 Supplement 18 · Efficacy · priority review LabelReviewSummary Review
- Oct 29, 2007 Supplement 17 · Efficacy · priority review LabelReviewPediatric Written Request
- Mar 1, 2005 Supplement 5 · Efficacy LabelLetter
- Sep 29, 2004 Supplement 2 · Efficacy LabelReviewLetter
- Aug 28, 2003 Supplement 1 · Efficacy LetterLabelReview
- Nov 15, 2002 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelReviewOther Important Information from FDA
6 products under this application
- ABILIFY · ARIPIPRAZOLE 2MG · TABLET, ORAL · Prescription · TE AB
- ABILIFY · ARIPIPRAZOLE 30MG · TABLET, ORAL · Prescription · TE AB
- ABILIFY · ARIPIPRAZOLE 15MG · TABLET, ORAL · Prescription · TE AB
- ABILIFY · ARIPIPRAZOLE 5MG · TABLET, ORAL · Prescription · TE AB
- ABILIFY · ARIPIPRAZOLE 20MG · TABLET, ORAL · Prescription · TE AB
- ABILIFY · ARIPIPRAZOLE 10MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Aripiprazole" as an intervention, any sponsor and status, largest first.
- Sequential Multiple Assignment Randomized Trial for Bipolar DepressionPivotal-lookingActive, not recruiting
Massachusetts General HospitalAcademic, hospital or other
NCT06433635 · 2,726 participants (planned) · Start Oct 1, 2024 · Primary completion Feb 28, 2030
Drug: Cariprazine; Aripiprazole/Escitalopram combination and 2 more · For: Bipolar I Disorder; Depression
Sites: Birmingham, Alabama; Bloomington, Indiana; Baltimore, Maryland · 18 sites in all
- Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia IndividualsStatus unknown
Tianjin Medical University General HospitalAcademic, hospital or other
NCT03790085 · 2,700 participants (planned) · Start Sep 1, 2018 · Primary completion Jun 30, 2020
Drug: Risperidone; Olanzapine and 1 more · For: Schizophrenia; Major Depressive Disorder; Anxiety Disorders
Sites: Tianjin, China
- Pragmatic Trial of Obsessive-compulsive DisorderPivotal-lookingRecruiting
Shanghai Mental Health CenterAcademic, hospital or other
NCT04539951 · 1,600 participants (planned) · Start Sep 22, 2020 · Primary completion Jun 30, 2027
Drug: Sertraline 200 milligram(mg); Sertraline 300 milligram(mg) and 4 more · For: Obsessive-Compulsive Disorder
Sites: Shanghai, China
- VA Augmentation and Switching Treatments for Improving Depression OutcomesPivotal-lookingCompleted
VA Office of Research and DevelopmentFederal agency
NCT01421342 · 1,522 participants · Start Dec 2012 · Primary completion Aug 2015
Drug: Switching: Bupropion-SR; Augmenting: Antidepressant + Bupropion-SR and 1 more · For: Major Depressive Disorder
Sites: Tuscaloosa, Alabama; Phoenix, Arizona; Tucson, Arizona · 35 sites in all
- A Study of Aripiprazole (Abilify) in Patients With Bipolar ManiaPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00261443 · 1,270 participants · Start Sep 2005 · Primary completion Jun 2009
Drug: Lithium or Valproate with placebo (PBO); Lithium or Valproate with Aripiprazole · For: Bipolar Disorder
Sites: Tuscaloosa, Alabama; Anaheim, California; Cerritos, California · 83 sites in all
- A Study of Adjunctive Aripiprazole in Patients With Major Depressive DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00095823 · 1,200 participants · Start Jun 2004 · Primary completion Aug 2006
Drug: Antidepressant + Placebo; Antidepressant + Aripiprazole · For: Major Depressive Disorder
Sites: Garden Grove, California; Northridge, California; Washington D.C., District of Columbia · 20 sites in all
- A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric PracticesPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00237939 · 1,200 participants · Start Sep 2002 · Primary completion Nov 2006
Drug: Aripiprazole · For: Schizophrenia
Sites: Antwerp, Belgium; Brussels, Belgium; Diest, Belgium · 20 sites in all
- A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed EpisodePivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00277212 · 1,169 participants · Start Dec 1, 2005 · Primary completion Jul 1, 2009
Drug: Lamotrigine + Aripiprazole; Lamotrigine + Placebo · For: Bipolar Disorder
Sites: Birmingham, Alabama; Tucson, Arizona; Anaheim, California · 66 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective8,220
- weight increased7,537
- off label use7,367
- anxiety5,051
- product use in unapproved indication4,908
- fatigue4,193
- suicidal ideation4,038
- nausea4,005
- depression3,968
- insomnia3,832
- drug interaction3,695
- tremor3,625
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,521 |
| 2005 | 1,783 |
| 2006 | 927 |
| 2007 | 1,986 |
| 2008 | 1,061 |
| 2009 | 6,101 |
| 2010 | 2,518 |
| 2011 | 4,124 |
| 2012 | 4,193 |
| 2013 | 3,267 |
| 2014 | 6,448 |
| 2015 | 7,439 |
| 2016 | 7,002 |
| 2017 | 12,295 |
| 2018 | 9,454 |
| 2019 | 6,382 |
| 2020 | 6,054 |
| 2021 | 6,740 |
| 2022 | 5,661 |
| 2023 | 5,988 |
| 2024 | 6,012 |
| 2025 | 5,563 |
| 2026 | 4,646 |
Recalls
5 FDA enforcement reports for this application.
Apr 9, 2024 · Class III · Ongoing
Cross Contamination with Other Products
Apr 9, 2024 · Class III · Ongoing
Cross Contamination with Other Products
Apr 9, 2024 · Class III · Ongoing
Cross Contamination with Other Products
Apr 9, 2024 · Class III · Ongoing
Cross Contamination with Other Products
Nov 2, 2012 · Class II · Terminated
CGMP Deviations: A drum of Abilify 30 mg Tablets rejected during the compression stage was not segregated from the other portion of the lot and was inadvertently shipped, packaged and distributed.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Abilify (Aripiprazole)
2024 spending
$7.1M
Beneficiaries
1,480
7,139 claims
Per beneficiary
$4,781
$22.53 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $24,481,911 |
| 2021 | $20,484,851 |
| 2022 | $13,141,218 |
| 2023 | $11,882,943 |
| 2024 | $7,075,288 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2021 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis.
Nuñez NA, Joseph B, Pahwa M, et al. · J Affect Disord 2022 · Network Meta-Analysis, Research Support, N.I.H., Extramural
- Adjunctive Antipsychotics in Major Depressive Disorder: A Systematic Review and Network Meta-Analysis.
McIntyre RS, Stahl SM, Shim SR, et al. · JAMA Psychiatry 2026 · Systematic Review, Network Meta-Analysis
- Efficacy, acceptability and side-effects of oral versus long-acting- injectables antipsychotics: Systematic review and network meta-analysis.
Wang D, Schneider-Thoma J, Siafis S, et al. · Eur Neuropsychopharmacol 2024 · Systematic Review, Network Meta-Analysis
- Systematic Review and Meta-analysis: Efficacy of Pharmacological Interventions for Irritability and Emotional Dysregulation in Autism Spectrum Disorder and Predictors of Response.
Salazar de Pablo G, Pastor Jordá C, Vaquerizo-Serrano J, et al. · J Am Acad Child Adolesc Psychiatry 2023 · Systematic Review, Meta-Analysis
Sponsor: Otsuka
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.